Cancer Research

The $15 billion expansion of the Roche-Hansoh partnership signals a massive shift toward multi-program antibody-drug conjugate portfolios rather than traditional single-asset licensing deals. This momentous agreement, finalized in late 2026, represents a fundamental restructuring of how global

Decision-curve analysis suggests that multiparametric MRI fusion models provide a higher clinical net benefit than current standard-of-care preoperative staging methods. In 2026, the landscape of gynecological oncology continues to evolve away from a one-size-fits-all surgical approach, moving

Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every

Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent

The persistent challenge of treating advanced HPV16-positive malignancies has driven medical science toward a more personalized approach that prioritizes early detection of treatment efficacy through minimally invasive methods. In the current landscape of oncology, researchers are increasingly

Triple-negative breast cancer remains a significant therapeutic challenge due to its aggressive nature and the absence of common hormonal receptors. Because patients lack estrogen, progesterone, and HER2 receptors, standard endocrine therapies and HER2-targeted treatments are ineffective, leaving